<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - RIVAROXABAN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>RIVAROXABAN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of venous thromboembolism following knee replacement surgery</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10 mg once daily for 2 weeks, to be started 6&#8211;10 hours after surgery.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of venous thromboembolism following hip replacement surgery</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10 mg once daily for 5 weeks, to be started 6&#8211;10 hours after surgery.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Initial treatment of deep-vein thrombosis</span>,
                <span class="indication">Initial treatment of pulmonary embolism</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 15 mg twice daily for 21 days, to be taken with food.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Continued treatment of deep-vein thrombosis (following initial treatment)</span>,
                <span class="indication">Continued treatment of pulmonary embolism (following initial treatment)</span>,
                <span class="indication">Prophylaxis of recurrent deep-vein thrombosis</span>,
                <span class="indication">Prophylaxis of recurrent pulmonary embolism</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                20 mg once daily, to be taken with food.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of stroke and systemic embolism in patients with non-valvular atrial fibrillation and with at least one of the following risk factors: congestive heart failure, hypertension, previous stroke or transient ischaemic attack, age &#8805; 75 years, or diabetes mellitus</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                20 mg once daily, to be taken with food.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of atherothrombotic events in acute coronary syndrome (with aspirin alone or aspirin and clopidogrel)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2.5 mg twice daily usual duration 12 months.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>For information on changing from, or to, other anticoagulants&#8212;consult product literature.</p>
            </section>
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Rivaroxaban is a direct inhibitor of activated factor X (factor Xa).</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid&#8212;toxicity in <i>animal</i> studies.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Avoid in liver disease with coagulopathy.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>For <i>treatment of deep-vein thrombosis or pulmonary embolism and prophylaxis of recurrent deep-vein thrombosis and pulmonary embolism</i>, initially 15&#8239;mg twice daily for 21 days, then 20&#8239;mg once daily (but consider reducing to 15&#8239;mg once daily if risk of bleeding outweighs risk of recurrent deep-vein thrombosis or pulmonary embolism) if creatinine clearance 15&#8211;49&#8239;mL/minute.</p><p>For <i>prophylaxis of stroke and systemic embolism in atrial fibrillation,</i> reduce dose to 15&#8239;mg once daily if creatinine clearance 15&#8211;49&#8239;mL/minute.</p>
            </section>
        
            <section class="generalInformation">
              <p>For <i>prophylaxis of venous thromboembolism following knee or hip replacement surgery and prophylaxis of atherothrombotic events in acute coronary syndrome</i>, use with caution if creatinine clearance 15&#8211;29&#8239;mL/ minute.</p><p>Use with caution if concomitant use of drugs that increase plasma-rivaroxaban concentration (consult product literature).</p><p>Avoid if creatinine clearance less than 15&#8239;mL/minute; manufacturer recommends Cockroft and Gault formula to calculate creatinine clearance.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Active bleeding</li>
            <li>in <i>acute coronary syndrome</i>&#8212;previous stroke</li>
            <li>in <i>acute coronary syndrome</i>&#8212;transient ischaemic attack</li>
            <li>malignant neoplasms</li>
            <li>oesophageal varices</li>
            <li>recent brain surgery</li>
            <li>recent gastro-intestinal ulcer</li>
            <li>recent intracranial haemorrhage</li>
            <li>recent ophthalmic surgery</li>
            <li>recent spine surgery</li>
            <li>significant risk of major bleeding</li>
            <li>vascular aneurysm</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, constipation, diarrhoea, dizziness, dyspepsia, haemorrhage, headache, hypotension, nausea, pain in extremities, pruritus, rash, renal impairment, vomiting,
              </p>
              <p>
                <strong>uncommon:</strong> Angioedema, dry mouth, malaise, syncope, tachycardia, thrombocythaemia,
              </p>
              <p>
                <strong>rare:</strong> Jaundice, oedema,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>Tablets may be crushed and mixed with water or apple puree just before administration.</p>
            </section>
      </section>


      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA170</h3>
              <p outputclass="title">Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (April 2009)</p> <p>Rivaroxaban is an option for the prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery.</p><xref format="html" href="http://www.nice.org.uk/TA170">www.nice.org.uk/TA170</xref>
                <a href="http://www.nice.org.uk/TA170" target="_blank">www.nice.org.uk/TA170</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA256</h3>
              <p outputclass="title">Rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation (May 2012)</p> <p>Rivaroxaban is an option for the prevention of stroke and systemic embolism (in accordance with its licensed indication) in patients with non-valvular atrial fibrillation and with at least one of the following risk factors:</p> <ul> <li>previous stroke or transient ischaemic attack</li> <li>congestive heart failure</li> <li>age &#8805;75 years</li> <li>diabetes mellitus</li> <li>hypertension</li> </ul> <p>The risks and benefits of rivaroxaban compared with warfarin should be discussed with the patient.</p><xref format="html" href="http://www.nice.org.uk/TA256">www.nice.org.uk/TA256</xref>
                <a href="http://www.nice.org.uk/TA256" target="_blank">www.nice.org.uk/TA256</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA261</h3>
              <p outputclass="title">Rivaroxaban for the treatment of deep-vein thrombosis and prevention of recurrent deep-vein thrombosis and pulmonary embolism (July 2012)</p> <p>Rivaroxaban is an option for the treatment of deep-vein thrombosis and prevention of recurrent deep-vein thombosis and pulmonary embolism in adults after diagnosis of acute deep-vein thrombosis.</p><xref format="html" href="http://www.nice.org.uk/TA261">www.nice.org.uk/TA261</xref>
                <a href="http://www.nice.org.uk/TA261" target="_blank">www.nice.org.uk/TA261</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA287</h3>
              <p outputclass="title">Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (June 2013)</p> <p>Rivaroxaban is an option for treating pulmonary embolism and preventing recurrent deep-vein thrombosis and pulmonary embolism in adults.</p><xref format="html" href="http://www.nice.org.uk/TA287">www.nice.org.uk/TA287</xref>
                <a href="http://www.nice.org.uk/TA287" target="_blank">www.nice.org.uk/TA287</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA335</h3>
              <p outputclass="title">Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (March 2015)</p> <p>Rivaroxaban is an option within its marketing authorisation, in combination with aspirin plus clopidogrel or aspirin alone, for preventing atherothrombotic events in patients who have had an acute coronary syndrome with elevated cardiac biomarkers.</p> <p>The patient's risk of bleeding should be carefully assessed before treatment is initiated and the risks and benefits of rivaroxaban in combination with aspirin plus clopidogrel or with aspirin alone, compared with aspirin plus clopidogrel or aspirin alone should be discussed with the patient.</p> <p>A decision on continuation of treatment should be taken no later than 12 months after starting treatment.</p><xref format="html" href="http://www.nice.org.uk/TA335">www.nice.org.uk/TA335</xref>
                <a href="http://www.nice.org.uk/TA335" target="_blank">www.nice.org.uk/TA335</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Anaesthesia with postoperative indwelling epidural catheter (risk of paralysis&#8212;monitor neurological signs and wait at least 18 hours after rivaroxaban dose before removing catheter and do not give next dose until at least 6 hours after catheter removal)
          </li>
          <li>
            bronchiectasis
          </li>
          <li>
            prosthetic heart valve (efficacy not established)
          </li>
          <li>
            risk of bleeding
          </li>
          <li>
            rivaroxaban should not be used as an alternative to unfractionated heparin in pulmonary embolism in patients with haemodynamic instability, or who may receive thrombolysis or pulmonary embolectomy
          </li>
          <li>
            severe hypertension
          </li>
          <li>
            vascular retinopathy
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Patients should be monitored for signs of bleeding or anaemia; treatment should be stopped if severe bleeding occurs.</p>
            </section>
            <section class="patientParameters">
              <p>No routine anticoagulant monitoring required (INR tests are unreliable).</p>
            </section>
      </section>


      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Low-dose rivaroxaban, in combination with aspirin alone <i>or</i> aspirin and clopidogrel, is licensed for the prevention of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers. Treatment should be started as soon as possible after the patient has been stabilised following the acute coronary event, at the earliest 24 hours after admission to hospital, and at the time when parenteral anticoagulation therapy would normally be discontinued; the usual duration of treatment is 12 months.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of RIVAROXABAN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP77297"><a href="../medicinalForm/PHP77297.html" data-target="#PHP77297" data-action="load">Tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
